免疫特征与肌层浸润性膀胱癌新辅助化疗免疫疗法的反应相关。
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.
发表日期：2024 May 24
作者：
Wolfgang Beckabir, Mi Zhou, Jin Seok Lee, Steven P Vensko, Mark G Woodcock, Hsing-Hui Wang, Sara E Wobker, Gatphan Atassi, Alec D Wilkinson, Kenneth Fowler, Leah M Flick, Jeffrey S Damrauer, Michael R Harrison, Karen P McKinnon, Tracy L Rose, Matthew I Milowsky, Jonathan S Serody, William Y Kim, Benjamin G Vincent
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS
摘要：
基于顺铂的新辅助化疗是肌层浸润性膀胱癌 (MIBC) 的标准治疗方法。单独使用免疫检查点抑制 (ICI) 以及 ICI 与化疗相结合，在新辅助治疗中已证明有希望的病理缓解 (
Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC). Immune checkpoint inhibition (ICI) alone, and ICI in combination with chemotherapy, have demonstrated promising pathologic response (